PharmaDrug Engages Octagon Media and Affiliated Wall Street Reporter for Investor Marketing Campaign
Toronto, Ontario--(Newsfile Corp. - January 20, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, announces that it has engaged Octagon Media Corp to assist in a digital media advertising campaign coupled with an investor marketing program. As compensation,...
2022-01-20 8:00 AM EST
PharmaDrug Announces Resignation of Director
Toronto, Ontario--(Newsfile Corp. - January 13, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTC: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, announces that Mr. Robert Schwartz has resigned from the board of directors of the Company (the "Board"), and the Board has accepted his resignation. The Company...
2022-01-13 4:15 PM EST
PharmaDrug Announces Addition of Dr. Cindy Hutnik, President of the Canadian Glaucoma Society to Their Scientific Advisory Board to Enhance Ongoing DMT Studies to Treat Glaucoma
Toronto, Ontario--(Newsfile Corp. - December 13, 2021) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, pleased to announce the addition of Dr. Cindy Hutnik to its scientific and clinical advisory board. Dr. Hutnik will assist the Company in its ongoing efforts to...
2021-12-13 7:30 AM EST
Pharmadrug Announces Successful Completion of Pre-IND Meeting with FDA Regarding Proposed Development of Its Cepharanthine for Treatment of Mild to Moderate COVID-19 Infection
Toronto, Ontario--(Newsfile Corp. - November 30, 2021) - PharmaDrug Inc. (CSE: PHRX) (OT
2021-11-30 8:42 AM EST
PharmaDrug Provides Research Results and Initiates IND-Enabling Studies for Cepharanthine in the Treatment of Multiple Cancers
Toronto, Ontario--(Newsfile Corp. - November 18, 2021) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce positive resear
2021-11-18 7:30 AM EST
PharmaDrug Advances Psychedelics Program with Analogue DMT Formulations to Treat Eye Diseases
Toronto, Ontario--(Newsfile Corp. - November 5, 2021) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased
2021-11-05 8:43 AM EDT
PharmaDrug Expands Product Offering to Prepare for Potential Adult Use Market in Germany
Toronto, Ontario--(Newsfile Corp. - November 1, 2021) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that its 100% owned cannabis and controlled substance distributor Pharmadrug Production GmbH ("Pharmadrug Production") has expanded...
2021-11-01 7:30 AM EDT
PharmaDrug Commences Trading on the OTCQB Market in the United States
Toronto, Ontario--(Newsfile Corp. - October 20, 2021) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce it has qualified for trading on the OTCQB Venture Market (the "OTCQB") operated by the OTC Markets Group Inc. The Company's common...
2021-10-20 8:01 AM EDT
PharmaDrug Announces Positive Research Results for Cepharanthine in the Treatment of Multiple Cancers When Used Alone and in Combination with Chemotherapy
Toronto, Ontario--(Newsfile Corp. - October 15, 2021) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company
2021-10-15 8:00 AM EDT
PharmaDrug Announces pre-IND Meeting Request Granted by FDA for Oral Antiviral Drug Cepharanthine for the Treatment of COVID-19 Infection
Toronto, Ontario--(Newsfile Corp. - September 28, 2021) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that the Company has been granted a Pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) for...
2021-09-28 8:00 AM EDT
PharmaDrug's Super Smart Launches Slim MycoWeRx Brand of Functional Mushrooms
Toronto, Ontario--(Newsfile Corp. - September 23, 2021) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company") a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that its Super Smart division is launching its own premium blend of functional mushrooms. MycoWe℞ Infinite will initially debut...
2021-09-23 8:00 AM EDT
Biotech Veteran David Kideckel Joins the Board of PharmaDrug
Toronto, Ontario--(Newsfile Corp. - August 30, 2021) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that David Kideckel will be joining the board effective immediately. David joins PharmaDrug after nearly 20 years of combined...
2021-08-30 8:00 AM EDT
PharmaDrug Announces Clinical Research Collaboration with The Johns Hopkins University to Evaluate DMT in a Comparative Clinical Study
Toronto, Ontario--(Newsfile Corp. - August 25, 2021) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that the Company has entered into a Clinical Trial Agreement with The Johns Hopkins University (JHU) to conduct a clinical study...
2021-08-25 8:00 AM EDT
PharmaDrug Announces Appointment of Auditor
Toronto, Ontario--(Newsfile Corp. - August 6, 2021) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, today announced that Harbourside CPA, LLP (the "Successor Auditor") has been appointed as the Company's auditor effective as of August 6, 2021 until the...
2021-08-06 2:17 PM EDT
PharmaDrug Forms Research Collaboration with Terasaki Institute for Novel Ocular Drug Formulation Program to Deliver DMT and Other Tryptamines to Treat Eye Disease
Toronto, Ontario--(Newsfile Corp. - August 5, 2021) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that PharmaDrug has entered into a sponsored research agreement
2021-08-05 8:00 AM EDT
Pharmadrug Announces Positive Research Results of Cepharanthine to Treat Multiple Cancers
Toronto, Ontario--(Newsfile Corp. - July 28, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce the completion of their preclini
2021-07-28 8:51 AM EDT
PharmaDrug Announces Stock Ticker Symbol Change to (CSE: PHRX)
Toronto, Ontario--(Newsfile Corp. - July 23, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that it will change its ticker symbol from "BUZZ" to "PHRX". The Company expects the symbol change to take effect on August 3, 2021....
2021-07-23 8:00 AM EDT
PharmaDrug Reports Positive Preclinical Study Results of Cepharanthine to Treat Cancers
Toronto, Ontario--(Newsfile Corp. - July 14, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce interim positive results from its ongoing preclinical study evaluating the Company's patented enteric-coated formulation of...
2021-07-14 7:45 AM EDT
PharmaDrug Announces Change of Auditor
Toronto, Ontario--(Newsfile Corp. - July 12, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, today announced that MNP LLP (the "Former Auditor") has resigned as the Company's auditors, with the resignation being effective as of June 14, 2021. The...
2021-07-12 5:18 PM EDT
PharmaDrug Advances Product and Clinical Development of Cepharanthine to Treat Infectious Diseases Including COVID-19
Toronto, Ontario--(Newsfile Corp. - June 22, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that the Company has initiated preparation of a Pre-Investigational New Drug Application (pre-IND) for its patented enteric-coated...
2021-06-22 7:47 AM EDT